ST. PAUL, Minn.--(BUSINESS WIRE)--
Catheter-related bloodstream infections (CRBSI) are life-threatening for
patients and costly for the medical professionals and facilities caring
for them. 3M is pleased to announce that the U.S. Food and Drug
Administration (FDA) has recognized the efficacy of 3M™ Tegaderm™ CHG
Chlorhexidine Gluconate I.V. Securement Dressing in reducing CRBSI,
expanding the product’s 510(k) indication to include CRBSI reduction.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20170606005406/en/
3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing (Photo: 3M)
The expanded indication is supported by a randomized, multi-arm,
controlled clinical trial of 1,879 subjects that found Tegaderm CHG I.V.
Securement Dressing reduced CRBSI by 60 percent in patients with central
and arterial lines (p=0.020).1
“While we are making great strides in reducing CRBSI nationwide, these
preventable infections are still responsible for significant morbidity,
mortality and excess costs,” stated Pat Parks, MD, PhD, medical director
for 3M Critical and Chronic Care Solutions Division. “Successful CRBSI
prevention practices rely on dedicated clinicians using proven
technology, such as Tegaderm CHG I.V. Securement Dressing, in alignment
with current best practice standards.”
Tegaderm CHG I.V. Securement Dressing is the only transparent dressing
indicated and proven to reduce CRBSI and vascular catheter colonization
that aligns with evidence-based guidelines and practice standards. The
dressing provides four essential elements to cover and protect patients’
catheter sites and secure devices to skin.
-
Infection Reduction: Clinically proven to reduce CRBSI by 60
percent in patients with central and arterial lines. The dressing
features an integrated gel pad containing 2 percent w/w CHG, a
well-known antiseptic agent with broad spectrum antimicrobial and
antifungal activity that maintains antimicrobial activity for 10 days.
-
Site Visibility: Transparent film and gel pad allow for
continual site observation, enabling early identification of
complications at the insertion site.
-
Consistent Application: Integrated CHG gel pad and dressing
design ensure standardized, correct application.
-
Catheter Securement: Designed to minimize catheter movement and
dislodgement.
“Providing effective, proven technology such as Tegaderm CHG I.V.
Securement Dressing is just one of the ways that 3M partners with
clinicians to help them achieve their infection prevention goals,” said
Parks. “We also provide clinical expertise and tools to support training
and compliance, and engaging educational resources to help facilities
implement the latest evidence-based guidelines and standards.”
For more information about coordinating a Tegaderm CHG Dressing product
trial, please visit 3M.com/TegadermCHG.
3M and Tegaderm are trademarks of 3M Company.
About 3M
At 3M, we apply science in collaborative ways to
improve lives daily. With $30 billion in sales, our 90,000 employees
connect with customers all around the world. Learn more about 3M’s
creative solutions to the world’s problems at www.3M.com
or on Twitter @3M or @3MNewsroom.
1 Timsit JF et al. Randomized controlled trial of
chlorhexidine dressing and highly adhesive dressing for preventing
catheter-related infections in critically ill adults. Am J Crit Care
Med. 2012;186(12): 1272-1278 http://www.atsjournals.org/doi/pdf/10.1164/rccm.201206-1038OC.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170606005406/en/
Source: 3M